Achieve Life Sciences Inc ACHV
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Achieve Life Sciences Announces Changes in Executive Leadership and Board of Directors
-
Achieve Life Sciences Reports Financial Results for Second Quarter 2024 and Provides Corporate Update
-
Achieve Life Sciences Announces FDA Grants Breakthrough Therapy Designation to Cytisinicline for the Treatment of E-Cigarette or Vaping Nicotine Dependence
-
Achieve Life Sciences Announces $20M Loan Refinancing with Silicon Valley Bank
-
Achieve Life Sciences to Announce Second Quarter Financial Results and Host Conference Call and Webcast on August 13, 2024
-
Milestone Pharmaceuticals Refreshes Board of Directors
-
Achieve Life Sciences to Present at JonesHealthcare Seaside Summit 2024
-
Achieve Life Sciences Announces Addition to the U.S. Russell 3000® and Russell Microcap® Indexes
Trading Information
- Previous Close Price
- $4.38
- Day Range
- $4.40–4.52
- 52-Week Range
- $3.03–5.98
- Bid/Ask
- $4.55 / $4.61
- Market Cap
- $152.48 Mil
- Volume/Avg
- 85,389 / 203,015
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 22
Comparables
Valuation
|
Metric
|
ACHV
|
SLRN
|
CRMD
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 3.61 | 0.86 | 9.85 |
Price/Sales | — | — | 585.18 |
Price/Cash Flow | — | — | — |
Price/Earnings
ACHV
SLRN
CRMD
Financial Strength
|
Metric
|
ACHV
|
SLRN
|
CRMD
|
|---|---|---|---|
Quick Ratio | 4.47 | 7.77 | 4.12 |
Current Ratio | 4.56 | 7.86 | 4.79 |
Interest Coverage | −8.17 | — | −1,599.40 |
Quick Ratio
ACHV
SLRN
CRMD
Profitability
|
Metric
|
ACHV
|
SLRN
|
CRMD
|
|---|---|---|---|
Return on Assets (Normalized) | −55.43% | −31.90% | −66.44% |
Return on Equity (Normalized) | −110.53% | −34.95% | −77.20% |
Return on Invested Capital (Normalized) | −57.22% | −40.49% | −81.35% |
Return on Assets
ACHV
SLRN
CRMD
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Mrmkhlrf | Jfq | $554.5 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Jhbwmqg | Rqchnj | $119.6 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Zvskpmyf | Kvhwydh | $114.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Nbnkphrg | Xwsyk | $35.2 Bil | |||
| argenx SE ADR
ARGX
| Nddxrkhf | Bvry | $32.5 Bil | |||
| BioNTech SE ADR
BNTX
| Pcyskhvys | Wtwtx | $28.0 Bil | |||
| Moderna Inc
MRNA
| Tvrdlsrw | Hvfz | $24.6 Bil | |||
| United Therapeutics Corp
UTHR
| Kbqtfgfbc | Kbmr | $15.9 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Slmqcdxf | Htqfl | $13.4 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Nkqtjbwqyd | Tcgchw | $12.6 Bil |
United States